The Impact of Locoregional Therapy in Nonmetastatic Inflammatory Breast Cancer: A Population-Based Study
Background. Inflammatory breast cancer (IBC) is a rare but most aggressive breast cancer subtype. The impact of locoregional therapy on survival in IBC is controversial. Methods. Patients with nonmetastatic IBC between 1988 and 2013 were identified in the Surveillance, Epidemiology, and End Results...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | International Journal of Breast Cancer |
| Online Access: | http://dx.doi.org/10.1155/2018/6438635 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832556938678763520 |
|---|---|
| author | Mahvish Muzaffar Helen M. Johnson Nasreen A. Vohra Darla Liles Jan H. Wong |
| author_facet | Mahvish Muzaffar Helen M. Johnson Nasreen A. Vohra Darla Liles Jan H. Wong |
| author_sort | Mahvish Muzaffar |
| collection | DOAJ |
| description | Background. Inflammatory breast cancer (IBC) is a rare but most aggressive breast cancer subtype. The impact of locoregional therapy on survival in IBC is controversial. Methods. Patients with nonmetastatic IBC between 1988 and 2013 were identified in the Surveillance, Epidemiology, and End Results (SEER) registry. Results. We identified 7,304 female patients with nonmetastatic inflammatory breast cancer (IBC) who underwent primary tumor surgery. Most patients underwent total mastectomy with only 409 (5.6%) undergoing a partial mastectomy. In addition, 4,559 (62.4%) were also treated with radiation therapy. The patients who underwent mastectomy had better survival compared to partial mastectomy (49% versus 43%, p = 0.003). The addition of radiation therapy was also associated with improved 5-year survival (55% versus 40%, p < 0.001). Multivariate analysis showed that black race HR (1.22, 95% CI 1.18–1.35), ER negative status (HR 1.22, 95% CI 1.16–1.28), and higher grade (HR 1.14, 95% CI 1.07–1.20) were associated with poor outcome. Cox proportional hazards model showed that total mastectomy (HR 0.75, 95% CI 0.65–0.85) and radiation (HR 0.64, 95% CI 0.61–0.69) were associated with improved survival. Conclusions. Optimal locoregional therapy for women with nonmetastatic IBC continues to be mastectomy and radiation therapy. These data reinforce the prevailing treatment algorithm for nonmetastatic IBC. |
| format | Article |
| id | doaj-art-19255c51b96b422fbc110b784db4ba97 |
| institution | Kabale University |
| issn | 2090-3170 2090-3189 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Breast Cancer |
| spelling | doaj-art-19255c51b96b422fbc110b784db4ba972025-02-03T05:43:56ZengWileyInternational Journal of Breast Cancer2090-31702090-31892018-01-01201810.1155/2018/64386356438635The Impact of Locoregional Therapy in Nonmetastatic Inflammatory Breast Cancer: A Population-Based StudyMahvish Muzaffar0Helen M. Johnson1Nasreen A. Vohra2Darla Liles3Jan H. Wong4Department of Medicine, Division of Hematology/Oncology, East Carolina University Brody School of Medicine, Greenville, NC, USADepartment of Surgery, Division of Surgical Oncology, East Carolina University Brody School of Medicine, Greenville, NC, USADepartment of Surgery, Division of Surgical Oncology, East Carolina University Brody School of Medicine, Greenville, NC, USADepartment of Medicine, Division of Hematology/Oncology, East Carolina University Brody School of Medicine, Greenville, NC, USADepartment of Surgery, Division of Surgical Oncology, East Carolina University Brody School of Medicine, Greenville, NC, USABackground. Inflammatory breast cancer (IBC) is a rare but most aggressive breast cancer subtype. The impact of locoregional therapy on survival in IBC is controversial. Methods. Patients with nonmetastatic IBC between 1988 and 2013 were identified in the Surveillance, Epidemiology, and End Results (SEER) registry. Results. We identified 7,304 female patients with nonmetastatic inflammatory breast cancer (IBC) who underwent primary tumor surgery. Most patients underwent total mastectomy with only 409 (5.6%) undergoing a partial mastectomy. In addition, 4,559 (62.4%) were also treated with radiation therapy. The patients who underwent mastectomy had better survival compared to partial mastectomy (49% versus 43%, p = 0.003). The addition of radiation therapy was also associated with improved 5-year survival (55% versus 40%, p < 0.001). Multivariate analysis showed that black race HR (1.22, 95% CI 1.18–1.35), ER negative status (HR 1.22, 95% CI 1.16–1.28), and higher grade (HR 1.14, 95% CI 1.07–1.20) were associated with poor outcome. Cox proportional hazards model showed that total mastectomy (HR 0.75, 95% CI 0.65–0.85) and radiation (HR 0.64, 95% CI 0.61–0.69) were associated with improved survival. Conclusions. Optimal locoregional therapy for women with nonmetastatic IBC continues to be mastectomy and radiation therapy. These data reinforce the prevailing treatment algorithm for nonmetastatic IBC.http://dx.doi.org/10.1155/2018/6438635 |
| spellingShingle | Mahvish Muzaffar Helen M. Johnson Nasreen A. Vohra Darla Liles Jan H. Wong The Impact of Locoregional Therapy in Nonmetastatic Inflammatory Breast Cancer: A Population-Based Study International Journal of Breast Cancer |
| title | The Impact of Locoregional Therapy in Nonmetastatic Inflammatory Breast Cancer: A Population-Based Study |
| title_full | The Impact of Locoregional Therapy in Nonmetastatic Inflammatory Breast Cancer: A Population-Based Study |
| title_fullStr | The Impact of Locoregional Therapy in Nonmetastatic Inflammatory Breast Cancer: A Population-Based Study |
| title_full_unstemmed | The Impact of Locoregional Therapy in Nonmetastatic Inflammatory Breast Cancer: A Population-Based Study |
| title_short | The Impact of Locoregional Therapy in Nonmetastatic Inflammatory Breast Cancer: A Population-Based Study |
| title_sort | impact of locoregional therapy in nonmetastatic inflammatory breast cancer a population based study |
| url | http://dx.doi.org/10.1155/2018/6438635 |
| work_keys_str_mv | AT mahvishmuzaffar theimpactoflocoregionaltherapyinnonmetastaticinflammatorybreastcancerapopulationbasedstudy AT helenmjohnson theimpactoflocoregionaltherapyinnonmetastaticinflammatorybreastcancerapopulationbasedstudy AT nasreenavohra theimpactoflocoregionaltherapyinnonmetastaticinflammatorybreastcancerapopulationbasedstudy AT darlaliles theimpactoflocoregionaltherapyinnonmetastaticinflammatorybreastcancerapopulationbasedstudy AT janhwong theimpactoflocoregionaltherapyinnonmetastaticinflammatorybreastcancerapopulationbasedstudy AT mahvishmuzaffar impactoflocoregionaltherapyinnonmetastaticinflammatorybreastcancerapopulationbasedstudy AT helenmjohnson impactoflocoregionaltherapyinnonmetastaticinflammatorybreastcancerapopulationbasedstudy AT nasreenavohra impactoflocoregionaltherapyinnonmetastaticinflammatorybreastcancerapopulationbasedstudy AT darlaliles impactoflocoregionaltherapyinnonmetastaticinflammatorybreastcancerapopulationbasedstudy AT janhwong impactoflocoregionaltherapyinnonmetastaticinflammatorybreastcancerapopulationbasedstudy |